No Data
No Data
Genmab Says European Commission Grants Marketing Authorization for Tivdak as Cervical Cancer Treatment
Genmab and BridgeBio Pharma Announce Japan Approval for Their Treatments
Genmab Announces That The Japan Ministry Of Health, Labour And Welfare Has Approved TIVDAK For The Treatment Of Advanced Or Recurrent Cervical Cancer That Has Progressed On Or After Cancer Chemotherapy. TIVDAK Is the First And Only Antibody-Drug...
Genmab Announces Initiation of Share Buy-Back Program
Genmab To Vigorously Defend Against AbbVie's Trade Secret Misappropriation Claims
Top Gap Ups and Downs on Friday: MUFG, SONY, IBN and More